The case for & against
Bull & Bear analysis
Bearish
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) operates at the forefront of biotechnology and artificial intelligence, focusing on revolutionizing drug discovery. The company leverages extensive proprietary datasets and advanced AI models to discover new therapies aimed primarily at rare diseases like familial adenomatous polyposis (FAP). Recursion's unique integration of bioscience and AI positions it strategically within a rapidly growing theme of AI-driven healthcare solutions, emphasizing significant unmet needs in therapeutic areas.
Bull says
- ↑REC 4881 median polyp burden down 43% after three months in FAP trials
- ↑Generated over $500 M in partnership inflows from Roche Genentech and Sanofi
- ↑Reduced FY26 cash opex guidance to $375 M, boosting cost efficiency
- ↑$557 M cash balance provides runway into early 2028
- ↑Comfortable liquidity position may support further AI-driven discovery investments
- ↑Potential short-covering could lift shares on positive catalysts
Bear says
- ↓Q2 2026 revenue of $7.67 M fell short of expectations
- ↓EPS of –$0.25 missed the consensus estimate of –$0.24
- ↓Negative earnings yield and weak profitability signal profitability challenges
- ↓Regulatory path for FAP therapies remains uncertain with limited precedent
- ↓Rising competition from other AI drug discovery firms threatens moat
- ↓High share price volatility deters risk-averse investors amid mixed news
Investment themes with RXRX
Biotech↓ -1.57%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 11-09-2025bullish
Transcript signals
Bull points
- We saw not only reasonable safety, but we saw early signals of efficacy. We had one patient who had a reduction in their tumor that was sustained for six months or more and a number of patients who had stable disease.
- We saw very encouraging reduction in lesion size based on the subjective MRI measure and also encouraging trends in functional improvement in the modified Rankin score in this phase two study.
- we continue to advance the next generation of molecules towards the clinic or into the clinic with CTA and IND updates for multiple programs, including the IND clearance for LSD1 in small cell lung cancer, the CTA for MALT1 and B-cell malignancies.
Read full transcript analysis ›